Results Of A Phase 3 Study Show TORISEL Significantly ImprovedProgression-free Survival For Patients With Relapsed/refractory MantleCell Lymphoma

Data presented from a phase 3 clinical trial at the 44th Annual Meeting of the American Society of Clinical Oncology show that patients with relapsed and/or refractory (failed front line therapy and unresponsive to most recent treatment) mantle cell lymphoma (MCL) treated with TORISEL (temsirolimus), an mTOR (mammalian target of rapamycin) inhibitor, experienced a statistically significant improvement (153 per cent) in median progression-free survival (PFS), compared with single-agent therapy selected by the investigator. TORISEL is currently approved in Canada for the treatment of metastatic (advanced) renal cell carcinoma (RCC).

Mantle cell lymphoma is a rare but deadly form of non-Hodgkin's lymphoma. In 2008, approximately 7,000 Canadians will be diagnosed with non-Hodgkin's lymphoma and over 3,000 will die from the disease in 2008. Mantle cell lymphoma accounts for approximately six per cent of all non-Hodgkin's lymphoma cases.
..........
@lta
LINK to This SOURCE
..........
@lta
SEARCH This TOPIC
..........
ALTACITIES
..........
Consider What's Important,
Not Just What's Urgent

Comments

Popular posts from this blog

#MCL?▶ #SocialCurrentSee

#StemCell #Transplant▶ #SocialCurrentSee®

Canswer♥Worth®▶ #SocialCurrentSee®

Privacy Notice

Privacy Notice: The sites and blogs of ALTACITIES conform to these PRIVACY PRACTICES.